A propensity-weighted ICU study found comparator-dependent results for severe alcohol withdrawal in alcohol-associated liver disease.
What the source reports
The retrospective analysis compared 763 phenobarbital recipients with 2,863 benzodiazepine recipients before weighting. Overall mortality was similar, while mechanical ventilation and ICU stay favored phenobarbital. Those advantages were most apparent against short-acting benzodiazepines; comparisons with long-acting agents and high-risk liver-disease subgroups were less clearly different.
Limits and uncertainty
Treatment was not randomized. Weighting cannot remove unmeasured differences in withdrawal severity, clinician selection or treatment sequence. Grouping all benzodiazepines together can hide clinically relevant comparator differences. Similar mortality estimates do not establish equivalence for every patient with decompensated cirrhosis.
Implications for forensic review
For a treatment review, identify the actual agent and whether it was initial therapy, escalation or adjunctive treatment. A broad class comparison cannot determine that switching one individual would have prevented ventilation. The source supports a focused comparative question in a selected ICU population, with prospective confirmation still needed.
Source and related reading
Source reviewed: Safety and effectiveness of phenobarbital vs benzodiazepines for severe alcohol withdrawal in alcoho (PMC13019541). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Liver-Disease Opioid Study Used a Composite High-Risk Prescribing Definition.
Leave a Reply